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Abstract
Background: Glaucoma is a leading cause of irreversible blindness. Pathogenic variants in the Myocilin gene (MYOC)
cause juvenile open angle glaucoma (JOAG) in 8–36 % of cases, and display an autosomal dominant inheritance with
high penetrance. Molecular diagnosis is important for early identification as therapies are effective in minimizing vision
loss and MYOC variants can be associated to severe glaucoma. MYOC variants are usually inherited, however a fifth of
carriers do not report a family history. The occurrence of de novo MYOC variants is currently unknown.
Case presentation: In this study we investigated a 14 year old male Caucasian patient diagnosed with JOAG, and no
family history of glaucoma. A novel probably deleterious MYOC:p.(Pro254Leu) variant was identified in the index case.
This variant was not present in the parents or the siblings.
Conclusion: This is the second report of a de novo MYOC variant in a sporadic case of JOAG and it is currently
unknown if this mechanism occurs more frequently. This finding emphasizes the importance of screening
individuals with JOAG for MYOC mutations irrespective of a negative family history.
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Background
Glaucoma is one of the leading causes of irreversible
blindness affecting over 60 million individuals worldwide
[1]. Primary open angle glaucoma (POAG, MIM 137760)
is the most common type and is characterized by changes
in the optic nerve head with corresponding visual field
loss in the presence of an open anterior chamber angle
[2]. Juvenile open angle glaucoma (JOAG) refers to a
younger age at diagnosis usually defined by an onset
before 30–40 years old and associated with a more severe
phenotype [3, 4]. Therapies for POAG aim at controlling
intraocular pressure (IOP) and are usually effective in
minimizing disease progression [5–7]. However, the early
stages are often asymptomatic and half of the cases re-
main undiagnosed, making it challenging to implement
treatment before irreversible vision loss occurs.
Pathogenic sequence variants in the MYOC gene (MIM
601652) have been first described in association with
JOAG in 1997 [8]. Since then, they have been consistently
identified in 2–4 % of adult-onset POAG [9, 10] and in
8–36 % of JOAG [9, 11, 12] among different ethnicities.
MYOC comprises three exons which encode a protein
consisting of two major domains, an N-terminal
myosin-like domain and a C-terminal olfactomedin-like
domain [13]. Most disease causing variants are clus-
tered within exon 3 in the olfactomedin domain [14].
The pathophysiology is not fully understood but it has
been postulated that the accumulation of misfolded
proteins lead to endoplasmic reticulum stress, which
compromises the trabecular meshwork cells regulating
the IOP [15]. MYOC pathogenic variants are inherited
in an autosomal dominant fashion and are often associ-
ated with high IOP, younger age at diagnosis and strong
family history and can result in severe glaucoma and
blindness if left untreated [9, 10, 16].
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The majority of MYOC carriers report a family history
of glaucoma, however sporadic cases still account for
20 % of mutation carriers [9]. It is currently unknown
whether sporadic cases could be explained by de novo
variants. In this study, we report a JOAG sporadic case
with a novel de novo MYOC variant, and discuss the
occurrence of de novo variants in MYOC associated
glaucoma and the implications for the patient and his
family.
Case presentation
Clinical presentation
The pedigree of the family is shown in Fig. 1a. The index
case and his family were referred to the Australian and
New Zealand Registry of Advanced Glaucoma (ANZRAG)
through his treating ophthalmologist [17]. The proband
was a 14 year old Caucasian male patient (II-1). He was
referred to an ophthalmologist following a routine optom-
etrist review for his glasses prescription which revealed
high IOP. Following examination, he was diagnosed with
JOAG. His IOP at presentation were 31 mmHg in the
right eye and 32 mmHg in the left. His vertical cup-to-
disc ratio was 0.85 right and 0.8 left, and he had central
field loss involving fixation in the right eye (Humphrey
Field Analyzer, Zeiss) (Fig. 2a). His visual acuity was
20/20 in both eyes. His IOP was initially under
control with latanoprost and brimonidine/timolol.
However he underwent bilateral trabeculectomies
following his most recent IOP which were 40 mmHg.
Optic nerve appearances and retinal nerve fiber layer
loss (Spectralis®, Heidelberg Engineering) are depicted
in Fig. 2b and c. His parents and two siblings had
normal eye examinations.
Genetic testing
Genetic testing was performed through the National
Association of Testing Authorities (NATA) accredited
laboratories of SA Pathology at the Flinders Medical
Centre in Adelaide, Australia. The proband was sequenced
for the 3 coding exons of the MYOC gene as previously
described [9]. A heterozygous substitution of Thymine for
Cytosine at nucleotide 761 of the MYOC exon 3 coding
sequence was identified (MYOC:c.761C > T), encoding a
missense substitution of Proline to Leucine at position 254
(p.(Pro254Leu)) (Fig. 1b). No other variants were identi-
fied in the MYOC gene of the proband. JOAG can also be
associated with CYP1B1 variants [18]. The coding region
of the CYP1B1 gene was sequenced to exclude other
causative genes. No disease-causing variants were identi-
fied in CYP1B1.
The p.(Pro254Leu) variant is novel since it was absent
from the MYOC Database (www.myocilin.com), NCBI
dbSNP (www.ncbi.nlm.nih.gov/SNP/), and the Exome
Aggregation Consortium (http://exac.broadinstitute.org/)
which comprises exome sequence data spanning 60 706
unrelated individuals. A search of the scientific literature
also failed to identify any reference to this variant. How-
ever, a recent study reported a MYOC variant at the
same residue p.(Pro254Arg) in a patient with JOAG and
his affected mother [19]. SIFT and Polyphen-2 both
predicted this variant to be deleterious, with sequence
alignment demonstrating this position to be highly
conserved among vertebrates and other olfactomedin
domain-containing proteins (Fig. 1c). MYOC is a well
characterized gene and codon position 254 resides in the
core hydrophobic β-sheet belt of the olfactomedin
domain, which is important in protein-protein interac-
tions and is sensitive to aggregation in the presence of
substitutions [20]. The p.(Pro254Leu) variant is likely
pathogenic based on bioinformatics prediction, invariant
conservation of this residue, and characterization of the
protein structure. MYOC disease-causing variants can be
associated with severe glaucoma and blindness [9]. In
the view of the genetic result and the patient’s most
recent IOP, bilateral trabeculectomies were performed to
better control his IOP and minimize damage on his
optic nerves.
This variant was not detected in either parent of the
index case (Fig. 1b). The marker profile comparison
using the AmpFLSTR® Identifiler® PCR Amplification Kit
confirmed a profile consistent with the proband being
the biological child of the stated parents, indicating
p.(Pro254Leu) has arisen de novo in the proband. A de
novo MYOC pathogenic variant, p.(Val251Ala), has been
previously reported once in a JOAG case [21]. Interest-
ingly, this variant was located three amino acids from
p.(Pro254Leu) which was identified in this study.
While the occurrence of de novo pathogenic variants
in the genome vary considerably based on genomic loca-
tion, they are estimated to be common and have been
linked to many sporadic diseases [22]. Conditions with
dominant inheritance and modest fitness effect are more
commonly inherited than caused by de novo variants,
and this is the situation for MYOC associated glaucoma
which is usually inherited. For example, a founder effect
with an origin prior to the European settlement of
Australia has been suggested for the most commonMYOC
disease-causing variant, p.Gln368Ter, in some families
[23]. However, we previously reported that 20 % of MYOC
carriers do not report a family history of the disease [9].
Although this may be explained by individuals not being
aware of a diagnosis in their families, or relatives being
undiagnosed, it is possible that variants occur de novo in
some families. MYOC variants are often identified in older
individuals with parents usually unavailable for testing,
making it difficult to evaluate whether variants are inher-
ited or sporadic. This case is the second report of a de novo
MYOC variant, emphasizing that a sporadic variant should
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be considered when evaluating the likelihood of MYOC
variants in cases with no family history of JOAG or POAG.
De novo variants arise either in the germline or during
embryogenesis. If present in the germline cells of one par-
ent, they can represent a recurrence risk in siblings of the
variant carrier. We have previously shown that MYOC
genetic testing is important for early identification of at-
risk individuals and appropriate interventions to minimize
irreversible vision loss [9, 24]. To exclude a recurrence
risk resulting from germline mosaicism, both siblings of
the proband were subsequently tested for the MYOC
variant. Our testing revealed that neither sibling carried
theMYOC p.(Pro254Leu) variant, eliminating an inherited
risk of developingMYOC associated glaucoma.
Conclusion
In conclusion, we report a novel de novo MYOC variant
considered pathogenic in a patient with sporadic JOAG.
This is the second report of a MYOC de novo variant, and
it is currently unknown if this mechanism occurs more
Fig. 2 Clinical presentation of the index case. Glaucomatous defects in index case. a Visual field pattern deviation showing a superior arcuate
defect involving fixation in the right eye (Humphrey Field analyser, Zeiss). b Optic discs photos showing a right infratemporal notch and disc
haemorrhage. c Optical coherence tomography showing inferior retinal nerve fibre layer loss more prominent in the right eye than the left as
shown by the black arrow (Spectralis®, Heidelberg Engineering). RE: right eye, LE: left eye, TMP: temporal, SUP: superior, NAS: nasal, INF: inferior
(See figure on previous page.)
Fig. 1 Pedigree and genetic analysis. a Pedigree of the family. Round symbols indicate female; square symbols, male; fully filled symbols, open angle
glaucoma; unfilled symbols, unaffected; arrow, proband; plus/minus, presence/absence of the MYOC:p.(Pro254Leu) variant. b Chromatogram showing
the presence of MYOC:c.761C > T, p.(Pro254Leu) sequence variant in individual II-1 at the top (affected) and its absence in individual I-1 at the bottom
(unaffected). The black arrow marks the heterozygous variant. c. Alignment of MYOC protein sequences corresponding to residues 248 through 262
(NP_000252.1), against different species, and of different human olfactomedin proteins. The residue of interest, p.(Pro254Leu), is highlighted in yellow.
Reference sequences IDs of the genes/species aligned are shown in brackets
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frequently. This case also highlights that MYOC testing
should not be restricted to individuals with a positive fam-
ily history of glaucoma.
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